Navigation Links
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Date:9/15/2008

Topline Data from Phase 2 CEA and ACS Clinical Trials to be Released

Concurrent with AHA Presentation

SAN FRANCISCO, Sept. 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that two abstracts on the company's Phase 2 trials of VIA-2291 in patients with acute coronary syndrome (ACS) and in patients undergoing carotid endarterectomy (CEA) surgery, have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2008, taking place November 8-12 in New Orleans, LA.

Given AHA's embargo policy, the company will announce the proof of concept data from its CEA and ACS trials concurrent with the AHA sessions.

The presentation details are as follows:

Date/Time: Sunday, November 9, 2008: 5:45 p.m. CDT

Location: Ernest N. Morial Convention Center, Room 275-277

Session: Cardiovascular Seminar: Translational Trials and Strategies:

First in Man

Title: Three Months of Treatment with 5- Lipoxygenase Inhibitor VIA-2291

in Patients with Recent Acute Coronary Syndrome

Presented by: Jean-Claude Tardif, M.D., Professor and Director, Montreal

Heart Institute, Montreal, Canada

Date/Time: Sunday, November 9, 2008: 6:00 p.m. CDT

Location: Ernest N. Morial Convention Center, Room 275-277

Session: Cardiovascular Seminar: Translational Trials and Strategies:

First in Man

Title: Three Months of Treatment with 5-Lipoxygenase Inhibitor VIA- 2291

in Patients Scheduled for Elective Carotid Endarterectomy Surgery

Presented b
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets ... of the "Global Gynecological Devices Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... wide categories based on their operations. These ... different gynecological conditions that affect the female ...
(Date:9/19/2014)... 19, 2014  4WEB Medical announces the formal launch ... ankle osteotomy implants on the market today at ... meeting in Chicago .  The Osteotomy ... osteotomy needs with 74 size options included in one ... of only 15 to 18 implant sizes, which limited ...
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica US ... leading online community to help oncologists and other clinicians ... regarding the use of targeted therapies and immunotherapies, discusses ... and treatment.  Every September, Blood ... to raise awareness about blood cancers—helping to increase survival ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 34WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4
(Date:9/21/2014)... New York, NY (PRWEB) September 21, 2014 ... companies that help businesses and manufacturers perform tests on ... materials. In an increasingly regulated society, pressure on operators ... is higher than ever. A greater number of government ... testing of manufacturers' goods prior to sale. Although revenue ...
(Date:9/21/2014)... Over the past five years, the patent ... market, thereby cutting into revenue growth for the ... from Industry Canada, the loss of patent protection for ... billion in 2010 and 2012, respectively. “In response to ... hampered revenue growth, many pharmaceutical manufacturers have streamlined their ...
(Date:9/21/2014)... 22, 2014 The asthma market ... as it has become saturated with relatively efficacious ... corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), ... increasing generic competition. However, the launch of seven ... ICS/LABA therapies delivered by the next-generation inhalers will ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... September 21, 2014 Hundreds of ... forward in Pennsylvania’s Philadelphia Court of Common Pleas, ... the proceeding’s next monthly meeting has been scheduled ... 100300296) , “Our Firm is representing a number ... this litigation. We are pleased with its continued ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4
... a breakthrough discovery, American researchers have found some of the ... the womb. There have always been theories that unborn babies ... is read to or played music while still in the ... has been questionable in the past because there has been ...
... and Emcure Pharmaceuticals Ltd, a Pune-based company have jointly ... of hypertension. Announcing this at a press conference here ... Satish Mehta said the chirally pure S-Amlodipine, a product ... for the patients suffering from hypertension. ,Stating ...
... of almonds a day may improve your cholesterol. Previous ... of coronary heart disease by lowering cholesterol.// However, eating ... not recommended for people who need to restrict calories. ... almonds can reduce heart disease risk by lowering cholesterol. ...
... alone may be enough to treat some patients with ... studied 60 patients between 1985 and 1999.// Typical treatment ... surgery is not an option. ,In this study, ... for surgery to remove it. A combination radiation therapy ...
... helping your blood clot properly.It is so important that all ... The vitamin is found most commonly in leafy green ... do not have bacteria established, they need supplemental vitamin K. ... and 90 micrograms for women was set. Because no ...
... who will get Alzheimer's disease from healthy older people. Alzheimer's ... we can expect an increase in the number of cases ... seem to work best if they start early. This means ... University of Toronto have been analysing investigations on 1,000 Alzheimer's ...
Cached Medicine News:Health News:Almonds Improve Cholesterol 2
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Urinalysis Control is specifically designed for urine dipstick and microscopic testing. This control provides clear, visual positive and negative results, including hCG (pregnancy) and micr...
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Medicine Products: